Whole-Body diffusion-weighted MR imaging for assessment of Treatment response in Myeloma1

Radiology

Volumn 271, Issue 3, 2014, Pages 785-794

  Giles, Sharon L ^a   Messiou, Christina ^a   Collins, David J ^a,c,d   Morgan, Veronica A ^a   Simpkin, Catherine J ^a   West, Sharon ^b   Davies, Faith E ^b,d   Morgan, Gareth J ^b,d   DeSouza, Nandita M ^a,c,d  

^a Departments of Magnetic Resonance Imaging   (United Kingdom)

^b Departments of Haematooncology   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PARAPROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MEASUREMENT REPEATABILITY; MYELOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY MRI;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRAZINES; REPRODUCIBILITY OF RESULTS; THALIDOMIDE; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84901660665     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13131529     Document Type: Article

References (33)

1. International Myeloma Working Group. Criteria for the classifcation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-757.
2. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009;23(9):1545-1556.
3. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117(18):4701-4705.
4. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154(1):32-75.
5. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20(9):1467-1473.
6. Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coeff-cient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 2011;196(6):W790-W795.
7. Hillengass J, Bäuerle T, Bartl R, et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow in-fltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 2011;153(6):721-728.
8. Horger M, Weisel K, Bares R, et al. Modern imaging techniques during therapy in patients with multiple myeloma. Acta Radiol 2011;52(8):881-888.
9. Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O. Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma 2011;52(9):1630-1640.
10. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol 2011;29(14):1907-1915.
11. Hanrahan CJ, Christensen CR, Crim JR. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. RadioGraphics 2010;30(1): 127-142.
12. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur J Radiol 2009;70(3): 401-408.
13. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691-4695.
14. Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 2012;35(2):257-279.
15. Messiou C, Collins DJ, Morgan VA, Desou-za NM. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 2011;21(8):1713-1718.
16. Messiou CM, Giles SL, Collins DJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol 2012;85(1020):e1198-e1203.
17. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010;150(6): 647-662.
18. Collins DJ, Blackledge M. Techniques and optimisation. In: Koh DM, Thoeny HC, eds. Diffusion-weighted MR imaging: applications in the body. Berlin, Germany: Springer, 2010; 19-32.
19. Koh DM, Blackledge M, Padhani AR, et al. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 2012;199(2):252-262.
20. Fletcher RH, Fletcher S W. Clinical epidemiology: the essentials. 4th ed. Baltimore, Md.: Lippincott Williams & Wilkins, 2005.
21. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London, England: Blackwell Science, 1994.
22. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8(2):135-160.
23. Corona-Villalobos CP, Pan L, Halappa VG, et al. Agreement and reproducibility of apparent diffusion coeffcient measurements of dual-b-value and multi-b-value diffusion-weighted magnetic resonance imaging at 1.5 Tesla in phantom and in soft tissues of the abdomen. J Comput Assist Tomogr 2013;37(1):46-51.
24. Kim SY, Lee SS, Park B, et al. Reproduc-ibility of measurement of apparent diffusion coeffcients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging 2012;36(5): 1131-1138.
25. Kyriazi S, Collins DJ, Messiou C, et al. Met-astatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion co-effcients. Radiology 2011;261(1):182-192.
26. Koh DM, Blackledge M, Collins DJ, et al. Reproducibility and changes in the apparent diffusion coeffcients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009;19(11):2728-2738.
27. Bannas P, Hentschel HB, Bley TA, et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol 2012;22(9):2007-2012.
28. Hillengass J, Ayyaz S, Kilk K, et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012;97(11):1757-1760.
29. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2): 228-247.
30. Fenchel M, Konaktchieva M, Weisel K, Kraus S, Claussen CD, Horger M. Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study. Acad Radiol 2010;17(11):1326-1333.
31. Sommer G, Klarhöfer M, Lenz C, Scheffer K, Bongartz G, Winter L. Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression. Eur Radiol 2011;21(4):857-862.
32. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700-718.
33. Nemeth AJ, Henson JW, Mullins ME, Gonzalez RG, Schaefer P W. Improved detection of skull metastasis with diffusion-weighted MR imaging. AJNR Am J Neuroradiol 2007;28(6):1088-1092.